David Currow, PhD, MPH, FRACP, FAChPM, FAHMS of Flinders University, Adelaide, Australia talks about his poster at the 2016 World Conference of Lung Cancer (WCLC) summarizing two Phase III studies: ROMANA-1 and ROMANA-2 looking at efficacy and safety of anamorelin in cachexia for patients with non-small cell lung cancer (NSCLC) (NCT01387269, NCT01387282). These studies had identical eligibility criteria, primary outcomes and analysis. The results showed a sustained increase in lean body mass, an improvement in patient reported appetite, an improvement in fat mass across the 12 weeks of treatment in both studies as well as total mass. The studies show that in 900 people, randomized 2:1 in favor of anamorelin, a sustained benefit was seen with anamorelin. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.